Proteostasis Therapeutics Inc. has agreed to grant the licensing rights of an undisclosed target to Roche Holding AG's unit Genentech Inc. for over $100 million including up-front and milestone payments.
According to Proteostasis Therapeutics, the agreement will not include its cystic fibrosis transmembrane conductance modulators, which were granted fast-track designation by the U.S. Food and Drug Administration in April, and other programs and medicines related to cystic fibrosis. Cystic fibrosis is a rare and inherited disease characterized by the buildup of sticky mucus in the lungs and digestive system, which leads to persistent lung infections and other complications.
Under the agreement, Genentech will bear future research and development costs related to the program, and Proteostasis Therapeutics will receive royalties. The companies have not disclosed the full financial terms, target program or disease areas of focus.
Cambridge, Mass.-based Proteostasis Therapeutics develops small molecule therapeutics that can address malfunctions in protein handling processes within the cells, which can cause a wide range of diseases, including cancer.